中國衞生集團(00673.HK)擬向北京佑康健業醫療器械注資180萬元
格隆匯8月31日丨中國衞生集團(00673.HK)公吿，於2021年8月31日，公司、投資者中衞國際融資租賃（深圳）有限公司（公司全資附屬公司）、楊會軍先生、孫春雷先生、Best Robust及目標公司北京佑康健業醫療器械有限公司訂立協議，據此投資者及現有擁有人已有條件同意分別向目標公司注資人民幣1,800,000元及人民幣1,200,000元。
除注資之外，公司亦將向Best Robust（現有擁有人全資擁有的公司）支付代價，代價將通過公司按發行價每股0.10港元向Best Robust配發及發行2.5億股代價股份支付。隨完成注資之後，投資者及現有擁有人將分別擁有目標公司60%及40%股本權益。代價股份佔公司現有已發行股本約6.04%及經配發及發行代價股份擴大公司已發行股本約5.69%。
目標公司主要從事醫療器械及耗材分銷業務。目前，目標公司的業務主要於北京－河北地區開展，專注於兩大類別心臟電生理及泌尿外科器械產品。
經考慮目標公司業務的地理位置及各種產品，以及其持續發展和多元化至不同的產品，特別是於2021年之前七個月，董事認為，就地理位置及產品類型而論，透過注資獲得目標公司的多數權益為集團將其醫藥分銷業務組合多元化的良機，同時將增加集團的收入來源。
目標公司的客户基礎（包括北京－河北市場之知名醫院及醫療機構）以及目標公司的分銷權（包括知名醫療器械品牌）預計將與現有醫藥分銷業務產生協同效應。隨目標公司開始分銷狂犬疫苗之後及於完成之後，收購事項將令集團能夠進軍疫苗分銷業務。憑藉此機會，集團可能進一步發展其他疫苗產品的疫苗分銷業務，如破傷風疫苗、帶狀皰疹疫苗及HPV疫苗，從而於未來增強集團的盈利能力。董事會認為，協議的條款（包括注資及代價）屬公平合理，以及收購事項符合公司及股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
